Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.38) by 26.32 percent. This is a 37.78 percent increase over losses of $(0.45) per share from the same period last year.